Oncology Letters最新文献_第2页

FBXL5 depletion as a novel strategy against osteosarcoma: Evidence for MEK/ERK inhibition and enhanced therapeutic sensitivity. FBXL5缺失作为治疗骨肉瘤的新策略：MEK/ERK抑制和增强治疗敏感性的证据

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-24 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15726

Yan-Chao Ma, Wen-Ming Zhou, Yong-Qiang Shi, Yan-Bo Dong, Hai-Hong Zhang, Wei Nan

{"title":"FBXL5 depletion as a novel strategy against osteosarcoma: Evidence for MEK/ERK inhibition and enhanced therapeutic sensitivity.","authors":"Yan-Chao Ma, Wen-Ming Zhou, Yong-Qiang Shi, Yan-Bo Dong, Hai-Hong Zhang, Wei Nan","doi":"10.3892/ol.2026.15726","DOIUrl":"10.3892/ol.2026.15726","url":null,"abstract":"Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents. Despite standard treatments, including surgery and chemotherapy, the 5-year survival rate for metastatic OS remains <20%, underscoring the need for novel therapeutic targets. F-box and leucine-rich repeat protein 5 (FBXL5) is an E3 ubiquitin ligase that regulates iron homeostasis and exhibits complex functions across different tumors; however, its role in OS is still unclear. The present study employed the MG63 and 143B OS cell lines to investigate the oncogenic potential of FBXL5 through in vitro and in vivo experiments. Lentivirus-mediated FBXL5 knockdown significantly suppressed cell proliferation, migration and invasion, while promoting apoptosis. RNA sequencing analysis after FBXL5 silencing revealed significant alterations in the mitogen-activated protein kinase signaling pathway, particularly affecting the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) axis. Consequently, FBXL5 depletion reduced the expression and phosphorylation of Ras, Raf, MEK and ERK. In a mouse xenograft tumor model, FBXL5 knockdown inhibited tumor growth and reduced tumor volume. These findings suggest that FBXL5 promotes OS progression via regulation of the MEK/ERK signaling pathway, suggesting that it may be a useful therapeutic target and potential prognostic indicator; further validation in larger clinical cohorts is warranted.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"371"},"PeriodicalIF":2.1,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13329316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Androgen receptor drives lenvatinib resistance in hepatocellular carcinoma through transcriptional activation of EIF3I and a downstream ceRNA axis. 雄激素受体通过EIF3I和下游ceRNA轴的转录激活驱动肝细胞癌lenvatinib耐药。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-24 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15725

Changfeng Liu, Bing Zhang, Ye Jin, Zhi Chen, Miaomiao Wang, Zujian Wu

{"title":"Androgen receptor drives lenvatinib resistance in hepatocellular carcinoma through transcriptional activation of EIF3I and a downstream ceRNA axis.","authors":"Changfeng Liu, Bing Zhang, Ye Jin, Zhi Chen, Miaomiao Wang, Zujian Wu","doi":"10.3892/ol.2026.15725","DOIUrl":"10.3892/ol.2026.15725","url":null,"abstract":"Lenvatinib resistance is a notable clinical challenge in advanced hepatocellular carcinoma (HCC). Androgen receptor (AR) upregulation has been associated with poor prognosis and high invasiveness, particularly in AR-high HCC, yet its specific role in lenvatinib resistance remains unclear. The present study investigated whether AR confers resistance through regulating the circular RNA hsa_circ_0011385. Bioinformatic screening and experimental validation identified hsa_circ_0011385 as significantly upregulated in HCC tissues and AR-high cell lines. In established lenvatinib-resistant cells (MHCC97H-LR), AR, hsa_circ_0011385 and Akt3 were upregulated, while miR-212-5p was downregulated. Mechanistically, AR directly bound to the promoter of eukaryotic translation initiation factor 3 subunit I (EIF3I), the host gene of hsa_circ_0011385 and promoted its transcription. The upregulated hsa_circ_0011385 acted as a molecular sponge for miR-212-5p, thereby relieving its inhibition of the downstream oncogene Akt3. Functional assays showed that AR knockdown sensitized resistant cells to lenvatinib, inhibiting proliferation and migration while promoting apoptosis, whereas overexpressing hsa_circ_0011385 reversed these effects. To the best of our knowledge, the present study revealed for the first time that in AR-high HCC, AR drives lenvatinib resistance by activating the EIF3I/hsa_circ_0011385/miR-212-5p/Akt3 axis. This finding provides a new theoretical basis and potential therapeutic targets for overcoming lenvatinib resistance in this patient subset.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"370"},"PeriodicalIF":2.1,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13329717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A HRH1-YAP1 feedback loop drives pancreatic cancer progression and predicts therapeutic response. HRH1-YAP1反馈回路驱动胰腺癌进展并预测治疗反应。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-19 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15719

Junliang Chen, Jun Wen

{"title":"A HRH1-YAP1 feedback loop drives pancreatic cancer progression and predicts therapeutic response.","authors":"Junliang Chen, Jun Wen","doi":"10.3892/ol.2026.15719","DOIUrl":"10.3892/ol.2026.15719","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a dismal prognosis, characterized by an immunosuppressive tumor microenvironment and rapid development of chemoresistance. The present study investigated the histamine receptor H1 (HRH1), a G protein-coupled receptor, and its functional interplay with the transcriptional coactivator YAP1, a known driver of PDAC progression. Through integrated multi-omics analysis of data from TCGA, ICGC and GEO cohorts, the present study found that HRH1 was consistently overexpressed in PDAC, and its expression correlated with poor prognosis. Mendelian randomization analysis further suggested a causal relationship between the use of fexofenadine, an HRH1 antagonist, and a reduced risk of PDAC. Mechanistically, the present study identified a positive feedback loop in which HRH1 stabilizes and activates YAP1 signaling, while YAP1 knockdown downregulates HRH1 transcription, potentially through direct binding to the HRH1 promoter region. The present study constructed a prognostic model based on the HRH1-YAP1 axis by integrating a panel of 101 machine learning algorithms. The model, which includes HRH1, YAP1, ECT2, ITGB5, SHCBP1, MAML2, YWHAZ and ITGA2, effectively stratified patients into groups with differential risk. Patients in the high-risk group exhibited characteristics associated with worse outcomes, including KRAS mutations, chemoresistance, an immunosuppressive microenvironment and reduced responsiveness to immunotherapy. The present study establishes HRH1 as a novel therapeutic target in PDAC and proposes the repurposing of fexofenadine as a promising strategy to disrupt the oncogenic HRH1-YAP1 feedback loop.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"364"},"PeriodicalIF":2.1,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathological fracture of primary lymphoma of bone: A case report on diagnosis and novel surgical management. 原发性骨淋巴瘤病理性骨折1例诊断及新手术治疗。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-19 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15717

Duc Thanh Tran, Van Khanh Nguyen, Tran Quang Sang Nguyen, Minh Quang Dang, Van Anh Nguyen, The Hung Le, Tuyet Thanh Hai Tran, Van Cong Tran, Thi Thu Hien Tran, Trung Dung Tran

{"title":"Pathological fracture of primary lymphoma of bone: A case report on diagnosis and novel surgical management.","authors":"Duc Thanh Tran, Van Khanh Nguyen, Tran Quang Sang Nguyen, Minh Quang Dang, Van Anh Nguyen, The Hung Le, Tuyet Thanh Hai Tran, Van Cong Tran, Thi Thu Hien Tran, Trung Dung Tran","doi":"10.3892/ol.2026.15717","DOIUrl":"10.3892/ol.2026.15717","url":null,"abstract":"Primary lymphoma of bone (PLB) is an uncommon malignancy, representing ~4-5% of primary malignant bone tumors and 1% of all malignant lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype, accounting for ~80% of cases, and is highly curable with appropriate treatment. Therefore, accurate and timely diagnosis is crucial for favorable outcomes. The current study presents a 42-year-old male with primary DLBCL of the proximal humerus. The initial diagnosis was challenging due to overlapping morphological features with other small round cell tumors like Ewing's sarcoma and small cell osteosarcoma, particularly on small, decalcified biopsy samples. However, a definitive diagnosis was achieved through specific immunohistochemical markers. Following standard chemo-radiotherapy, the patient suffered a persistent, non-healing pathological fracture, resulting in severe functional shoulder impairment. This report details successful surgical management using a novel technique: A reverse shoulder megaprosthesis combined with a liquid nitrogen-treated autologous bone graft. This case report underscores PLB's diagnostic challenges and highlights a significant treatment-related complication. It presents a novel and effective surgical solution for managing pathological fractures in this context, emphasizing the necessity of a multidisciplinary, individualized approach to cure the disease, restore function and preserve the limb.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"362"},"PeriodicalIF":2.1,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application and challenges of chimeric antigen receptor T cell therapy in the treatment of acute myeloid leukemia (Review). 嵌合抗原受体T细胞治疗急性髓性白血病的应用和挑战（综述）。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-19 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15716

Jingjing Zhang, Feilin Wang, Dandan Sui, Ziyi Huang, Yijian Chen

{"title":"Application and challenges of chimeric antigen receptor T cell therapy in the treatment of acute myeloid leukemia (Review).","authors":"Jingjing Zhang, Feilin Wang, Dandan Sui, Ziyi Huang, Yijian Chen","doi":"10.3892/ol.2026.15716","DOIUrl":"10.3892/ol.2026.15716","url":null,"abstract":"Chimeric antigen receptor (CAR) T cell therapy is a rapidly evolving form of targeted immunotherapy that merges the antigen-recognition specificity of monoclonal antibodies with the potent cytotoxic function of T cells. While it has achieved remarkable clinical success in B cell hematologic malignancies, its application to acute myeloid leukemia (AML) remains limited by several key obstacles. These include the absence of AML-specific antigens, antigen escape, an immunosuppressive tumor microenvironment and pronounced intratumoral heterogeneity. Together, these challenges substantially hinder the efficacy and safety of CAR-T cell therapy in AML. The present review provides a comprehensive overview of current advancements in CAR-T cell therapy for AML, with particular emphasis on strategies to overcome existing barriers such as improved target antigen selection, CAR structural optimization and modulation of the tumor microenvironment. These insights aim to inform the development of next-generation CAR-T therapies with enhanced precision, persistence and therapeutic benefit in AML.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"361"},"PeriodicalIF":2.1,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salivary duct carcinoma with heterotopic ossification in the parotid gland: A case report. 涎腺导管癌伴腮腺异位骨化1例。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-19 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15718

Yutaro Fukuma, Mitsuaki Ishida, Akinori Sasaki, Tsuyoshi Jinnin, Tetsuya Terada, Shin-Ichi Haginomori, Yoshinobu Hirose

{"title":"Salivary duct carcinoma with heterotopic ossification in the parotid gland: A case report.","authors":"Yutaro Fukuma, Mitsuaki Ishida, Akinori Sasaki, Tsuyoshi Jinnin, Tetsuya Terada, Shin-Ichi Haginomori, Yoshinobu Hirose","doi":"10.3892/ol.2026.15718","DOIUrl":"10.3892/ol.2026.15718","url":null,"abstract":"Salivary duct carcinoma (SDC) is one of the most aggressive salivary gland carcinomas. Heterotopic ossification (HO) is the formation of mature bone in non-skeletal tissues. HO can occur in a number of neoplastic lesions. However, its occurrence is markedly rare in salivary gland neoplasms and to the best of our knowledge, SDC with HO has not yet been reported. Therefore, the present report describes the first reported case of SDC with HO in the parotid gland and reviews the clinicopathological features of salivary gland neoplasms with HO. A 38-year-old Japanese male presented with a mass in the left parotid region. Physical examination revealed a poorly mobile mass, measuring 2 cm, in the left parotid gland. Total left parotidectomy was performed. A number of metastases were observed in the bone and brain, despite postoperative anti-HER2 combination chemotherapy. Histopathological examination of the resected parotid gland tumour revealed invasive neoplastic growth comprising cribriform and papillary proliferations. These neoplastic cells exhibited a rich eosinophilic cytoplasm and large nuclei containing conspicuous nucleoli. In addition, the present report outlines peculiar finding in the presence of mature bone tissue within the tumour. Accordingly, a diagnosis of SDC with HO was made. Despite the detailed mechanisms underlying the occurrence of HO in salivary gland neoplasms remaining unclear, neoplastic myoepithelial cells may serve a role in the development of HO in pleomorphic adenoma and carcinoma ex pleomorphic adenoma. However, SDC exhibited no myoepithelial cell components, therefore the mechanism of HO in SDC may differ from that in PA.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"363"},"PeriodicalIF":2.1,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safe management of sequential chemotherapy in a hemodialysis patient with metastatic colorectal cancer: A case report. 转移性结直肠癌血液透析患者序贯化疗的安全管理：1例报告。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-18 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15714

Rika Sasaki, Nobuhito Hara, Yoshiki Kojitani, Yumi Yoshii, Masahide Ota, Shunsuke Okazaki, Masayuki Takeda

{"title":"Safe management of sequential chemotherapy in a hemodialysis patient with metastatic colorectal cancer: A case report.","authors":"Rika Sasaki, Nobuhito Hara, Yoshiki Kojitani, Yumi Yoshii, Masahide Ota, Shunsuke Okazaki, Masayuki Takeda","doi":"10.3892/ol.2026.15714","DOIUrl":"10.3892/ol.2026.15714","url":null,"abstract":"Managing chemotherapy in hemodialysis (HD) patients is clinically challenging due to altered pharmacokinetics and a higher risk of severe toxicity. Evidence on drug selection and dose titration in cancer patients undergoing HD is limited. The present study reported the case of a patient with metastatic colorectal cancer who safely received first-to third-line chemotherapy while on maintenance HD. Treatment was individualized based on drug characteristics and the dialysis schedule. Initial therapy consisted of reduced-dose capecitabine (1,000 mg/m2/day, days 1-14) plus oxaliplatin (70 mg/m2, day 1) in a 21-day cycle, which was administered for 2 cycles. This was followed by 14 cycles of irinotecan monotherapy (day 1 of a 14-day cycle); the dose was initiated at 120 mg/m2 and gradually reduced to 105 mg/m2 and then 90 mg/m2 based on toxicity. Third-line treatment involved 5 cycles of regorafenib (days 1-21 of a 28-day cycle), which was initiated at 40 mg/day and increased to 80 mg/day after confirming safety and tolerability. No life-threatening adverse events occurred during the treatment course. This case suggests that chemotherapy can be administered safely in selected HD patients when treatment is individualized, taking into account drug characteristics, dialysis-related factors and patient tolerance.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"358"},"PeriodicalIF":2.1,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13311902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148352719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of the preoperative lactate dehydrogenase-to-albumin ratio in patients with gastrointestinal cancer. 术前乳酸脱氢酶与白蛋白比值对胃肠道肿瘤患者的预后价值。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-18 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15715

Yean Yu, Li Yan, Kun Lv, Tianhui Huang

{"title":"Prognostic value of the preoperative lactate dehydrogenase-to-albumin ratio in patients with gastrointestinal cancer.","authors":"Yean Yu, Li Yan, Kun Lv, Tianhui Huang","doi":"10.3892/ol.2026.15715","DOIUrl":"10.3892/ol.2026.15715","url":null,"abstract":"Gastrointestinal cancer (GIC) remains a major clinical burden, and readily available biomarkers are needed to improve preoperative prognostic assessment and risk stratification. The present study aimed to evaluate the prognostic significance of the preoperative lactate dehydrogenase-to-albumin ratio (LAR) in patients with GIC. A comprehensive search was performed in PubMed, Embase and the Cochrane Library to identify relevant studies published from the date of database inception to March 20, 2025. The extracted outcomes included hazard ratios (HRs) for overall survival (OS) and recurrence-free survival (RFS) and odds ratios (ORs) for major postoperative complications. A total of five independent studies involving 6,379 patients were included in the present meta-analysis. A higher preoperative LAR was significantly associated with poorer OS [HR=1.90; 95% confidence interval (CI), 1.63-2.21; P<0.001]. Subgroup analysis confirmed the robustness of this association across analytical models, cancer types, countries and LAR cut-off values. A higher LAR was also associated with poorer RFS (HR=1.83; 95% CI, 1.52-2.20; P<0.001) and a higher risk of major postoperative complications (OR=2.36; 95% CI, 1.49-3.74; P<0.001). In conclusion, preoperative LAR may serve as a useful prognostic biomarker for survival outcomes in patients with GIC. Incorporating this readily available and low-cost biomarker into routine preoperative assessment may help improve perioperative risk stratification and guide postoperative management.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"360"},"PeriodicalIF":2.1,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-CD20 and -PD-1 antibody effects on proliferation, apoptosis and cell cycle of endometrial cancer cells. 抗cd20和-PD-1抗体对子宫内膜癌细胞增殖、凋亡和细胞周期的影响。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-17 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15712

Jinqiu Su, Jiayuan Du, Yaojie Yu, Mei Feng, Qiuyue Huang, Bing Liu, He Wang

{"title":"Anti-CD20 and -PD-1 antibody effects on proliferation, apoptosis and cell cycle of endometrial cancer cells.","authors":"Jinqiu Su, Jiayuan Du, Yaojie Yu, Mei Feng, Qiuyue Huang, Bing Liu, He Wang","doi":"10.3892/ol.2026.15712","DOIUrl":"10.3892/ol.2026.15712","url":null,"abstract":"The present study aimed to systematically evaluate the functional effects of the anti-CD20 antibody Rituximab and the programmed cell death 1 (PD-1/PDCD1) antibody Pembrolizumab on endometrial cancer (EC) cells. The expression levels of membrane spanning 4-domains A1 (MS4A1) and PDCD1 in EC tissues and cells were analyzed using the The Cancer Genome Atlas database with R programming language. The impacts of Rituximab and Pembrolizumab treatment on proliferation, apoptosis and cell cycle progression were assessed in Ishikawa and HEC-1A EC cell lines by means of CCK-8 assays and flow cytometry. Both MS4A1 and PDCD1 were significantly upregulated in EC tissues and cells compared with normal controls. Rituximab and Pembrolizumab demonstrated concentration-dependent inhibitory effects on the proliferation of EC cells, induced cell apoptosis and arrested cell cycle progression. Furthermore, the combination of Rituximab and Pembrolizumab resulted in enhanced and more potent suppression of cancer cell growth than either monotherapy alone. In conclusion, the combination of anti-CD20 antibody and PD-1 antibody exerts synergistic antiproliferative effects on EC cells in vitro.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"357"},"PeriodicalIF":2.1,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13311903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148352761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD47 monoclonal antibody enhances the inhibitory effect of anti-HER2 chimeric antigen receptor macrophages on ovarian cancer. CD47单克隆抗体增强抗her2嵌合抗原受体巨噬细胞对卵巢癌的抑制作用。

IF 2.1 4区医学

Oncology Letters Pub Date : 2026-06-17 eCollection Date: 2026-08-01 DOI: 10.3892/ol.2026.15711

Jie Qiao, Qing Kou, Ji Qiu

{"title":"CD47 monoclonal antibody enhances the inhibitory effect of anti-HER2 chimeric antigen receptor macrophages on ovarian cancer.","authors":"Jie Qiao, Qing Kou, Ji Qiu","doi":"10.3892/ol.2026.15711","DOIUrl":"10.3892/ol.2026.15711","url":null,"abstract":"Macrophages have garnered notable interest as therapeutic vehicles due to their innate phagocytic ability, tumor tropism, and pivotal role in linking innate and adaptive immunity. These attributes have led to the development of various macrophage-centered treatments. Among them, chimeric antigen receptor macrophages (CAR-Ms) have emerged as a promising adoptive cell therapy, demonstrating potential for clinical application in multiple solid tumors. However, their effector functions remain amenable to further enhancement. In the present study, anti-HER2 CAR-Ms were constructed using an adenoviral vector system. The specificity and antitumor efficacy against HER2+ ovarian cancer cells were assessed using flow cytometry. The effects of a CD47 monoclonal antibody (mAb) on CAR-M-mediated killing and phenotypic polarization were subsequently investigated. Additionally, the combined therapeutic benefit of CD47 mAb and anti-HER2 CAR-Ms was evaluated in a murine subcutaneous xenograft model of ovarian cancer. Anti-HER2 CAR-Ms specifically recognized and killed HER2-expressing ovarian cancer cells. The addition of CD47 mAb enhanced the phagocytic capacity, promoted a pro-inflammatory phenotype and inflammatory cytokine secretion in CAR-Ms. In vivo, combination therapy significantly reduced tumor burden in xenograft-bearing mice. Collectively, these findings indicate that the combination of CAR-Ms with CD47 blockade offers a robust and promising strategy for personalized targeted therapy in solid tumors.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 2","pages":"356"},"PeriodicalIF":2.1,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13311928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148352678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0